Triple colour reagent for studying canine T cells
AbD Serotec
Antibodies to canine T and B cell markers
To assist researchers AbD Serotec offers singular antibodies to canine T and B cell markers, plus a range of dual colour reagents for detecting CD3/CD4, CD4/CD8 and CD3/CD8
In the canine veterinary field, antibodies for phenotyping T and B cells are used to investigate a variety of diseases including viral infections (eg, Canine Distemper Virus), parasitic infections (eg, Leishmaniosis) and various lymphomas.
In particular antibodies to CD3, CD4, CD8 (T cells) and CD21-like (B cells) are used to determine the expression profiles of lymphocytes in blood samples taken from dogs with multi systemic lymphomas.
AbD Serotec has also recently released its novel product TC014, which is a triple colour reagent consisting of FITC, RPE and Alexa Fluor 647 conjugated monoclonal antibodies mixed in optimal ratios.
This product, which is currently unique to AbD Serotec, can be used for the simultaneous detection of CD3, CD4 and CD8.
With three conjugated antibodies in one reagent, this exclusive product provides a cost effective option to the customer.
TC014 utilises clones CA17.A12, YKIX302.9 and YCATE55.9 which are also available as individual antibodies with a host of conjugates.
More stories
Antibody targets PTEN-induced putative kinase
AbD Serotec has announced the availability of a new HUCAL monoclonal antibody targeting PTEN-induced putative kinase 1 (PINK1).
AbD Serotec supplies custom monoclonal antibodies
AbD Serotec has signed a two-year contract for the supply of custom monoclonal antibodies with Research Councils UK Shared Services Centre (RCUK SSC).
Potent anti-PTH antibody for diagnostic purposes
ABD Serotec, a unit of Morphosys, has gained access to a potent anti-PTH antibody for commercial use in research and diagnostic applications.
ABD Serotec progresses in antibody generation
ABD Serotec has demonstrated significant progress using the HuCAL-based technology platform to generate custom-made monoclonal antibodies for research and diagnostic use.
Alliance aims for temperature-stable antibodies
AbD Serotec has initiated a research collaboration with Find, a Swiss foundation that develops, evaluates and accelerates the implementation of diagnostic tools for poverty-related diseases.
